Dare Bioscience, INC Form 4 insider transactions

Dare Bioscience, Inc. reports that Director Gregory W. Matz was granted restricted stock units in lieu of cash compensation for board services.

Dare Bioscience, Inc. reports that Director William H. Rastetter was granted restricted stock units (RSUs) as compensation for board services.

Director William H. Rastetter was granted 10,000 stock options in Dare Bioscience, Inc. as part of standard compensation.

Director Susan L. Kelley was granted 10,000 stock options in Dare Bioscience, Inc. as part of a standard equity compensation package.

Dare Bioscience director Robin Steele was granted 10,000 stock options as part of standard equity compensation.

Director Gregory W. Matz was granted 10,000 stock options in Dare Bioscience, Inc. as part of his compensation.

Director Jessica D. Grossman was granted 10,000 stock options in Dare Bioscience, Inc. as part of a standard equity compensation.

Dare Bioscience CEO Sabrina Martucci Johnson acquired 172,000 employee stock options at an exercise price of $1.81, vesting over 48 months.

Dare Bioscience's Chief Accounting Officer, MarDee Haring-Layton, was granted 49,000 employee stock options with an exercise price of $1.81.

Dare Bioscience, Inc. granted 57,000 employee stock options to Chief Accounting Officer MarDee Haring-Layton as a retention award.

William H. Rastetter, a Director at Dare Bioscience, Inc., was granted 4,500 stock options with an exercise price of $2.44, aligning his interests with shareholder value.

Dare Bioscience, Inc. Director Robin Joan Steele was granted 4,500 stock options with an exercise price of $2.44, vesting based on service or a change in control.

Dare Bioscience, Inc. Director Gregory W. Matz was granted 4,500 stock options with an exercise price of $2.44, vesting based on continued service and potential change of control.

Dare Bioscience, Inc. director Jessica D. Grossman was granted 4,500 stock options with an exercise price of $2.44, set to vest on the earlier of the first anniversary of the grant date or prior to the company's first annual meeting of stockholders after the grant.

Dare Bioscience Director Susan L. Kelley has acquired 4,500 stock options with an exercise price of $2.44, vesting based on service or a change in control.

Dare Bioscience's Chief Accounting Officer, MarDee Haring-Layton, was granted 38,000 stock options on January 28, 2025.

Dare Bioscience CEO, Sabrina Martucci Johnson, was granted 107,000 stock options on January 28, 2025, which vest over 48 months.

Jessica D. Grossman, a director of Dare Bioscience, acquired stock options for 40,000 shares on June 5, 2024.

Director Robin Joan Steele acquired 40,000 stock options in Dare Bioscience, Inc. on June 5, 2024.

Director William H. Rastetter acquired 40,000 stock options in Dare Bioscience, Inc. on June 5, 2024.

Director Susan L. Kelley acquired 40,000 stock options in Dare Bioscience, Inc. on June 5, 2024.

Gregory W. Matz, a director of Dare Bioscience, acquired stock options for 40,000 shares on June 5, 2024.

John A. Fair, Chief Commercial Officer of Dare Bioscience, acquired 290,000 stock options on March 12, 2024.

Sabrina Martucci Johnson, CEO of Dare Bioscience, acquired 750,000 employee stock options on March 12, 2024, exercisable over 48 months.

MarDee Haring-Layton, Chief Accounting Officer of Dare Bioscience, acquired stock options for 290,000 shares on March 12, 2024.